STOCK TITAN
  1. Home
  2. Sec-filings
  3. GH
  4. [Form 4] Guardant Health, Inc. Insider Trading Activity

Guardant Health (GH) HR chief exercises 46,300 options and sells 46,300 shares

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Guardant Health, Inc. executive Terilyn J. Monroe, Chief People Officer, exercised stock options covering 46,300 shares of common stock on 2026-08-12 (32,288 shares at an exercise price of $20.14 and 14,012 shares at $28.61). She then sold 46,300 common shares in multiple open-market or private transactions at weighted average prices ranging from $162.80 to $168.02. The exercised options were from awards granted on February 26, 2024 and November 8, 2024, each vesting over three years with 33% vesting after roughly one year and the remaining 67% in equal monthly installments over the next two years. The filing does not affirm trading under a Rule 10b5-1 plan.

Positive

  • None.

Negative

  • None.
Insider Monroe Terilyn J.
Role Chief People Officer
Sold 46,300 shs ($7.65M)
Approx. gross sale proceeds $7.65M
Approx. exercise cost $1.05M
Approx. pre-tax spread $6.59M
Type Security Shares Price Value
Exercise Stock Option (Right to Buy) F6 32,288 $0.00 $0.00
Exercise Stock Option (Right to Buy) F7 14,012 $0.00 $0.00
Exercise Common Stock 32,288 $20.14 $650K
Exercise Common Stock 14,012 $28.61 $401K
Sale Common Stock F1 3,704 $163.4141 $605K
Sale Common Stock F2 9,934 $164.2712 $1.63M
Sale Common Stock F3 19,014 $165.1578 $3.14M
Sale Common Stock F4 13,248 $166.1069 $2.20M
Sale Common Stock F5 400 $167.9188 $67K
Holdings After Transaction: Stock Option (Right to Buy) — 29,531 shares (Direct); Common Stock — 22,979 shares (Direct)
Footnotes (7)
  1. F1. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $162.80 to $163.78. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
  2. F2. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $163.81 to $164.805. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
  3. F3. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $164.825 to $165.82. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
  4. F4. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $165.85 to $166.825. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
  5. F5. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $167.695 to $168.02. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
  6. F6. This represents a stock option award granted on February 26, 2024 that vests over a three-year period. 33% of the shares subject to such award vested on January 2, 2025 and the remaining 67% of the shares vests in equal monthly installments over the remaining two-year period thereafter.
  7. F7. This represents a stock option award granted on November 8, 2024 that vests over a three-year period. 33% of the shares subject to such award vested on October 1, 2025 and the remaining 67% of the shares vests in equal monthly installments over the remaining two-year period thereafter.
Options exercised (shares) 46,300 shares Total derivative exercises (code M) on 2026-08-12
Shares sold 46,300 shares Total common shares sold in code S transactions on 2026-08-12
Exercise price 1 $20.14 per share Stock option for 32,288 shares expiring 2034-02-26
Exercise price 2 $28.61 per share Stock option for 14,012 shares expiring 2034-11-08
Sale tranche 1 3,704 shares at $163.4141 Weighted average price; trades from $162.80 to $163.78
Sale tranche 2 9,934 shares at $164.2712 Weighted average price; trades from $163.81 to $164.805
Sale tranche 3 19,014 shares at $165.1578 Weighted average price; trades from $164.825 to $165.82
Sale tranche 4 13,248 shares at $166.1069 Weighted average price; trades from $165.85 to $166.825
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
weighted average sales price per share financial
"Represents the weighted average sales price per share."
vests in equal monthly installments financial
"the remaining 67% of the shares vests in equal monthly installments"
open market or private transaction financial
"Sale in open market or private transaction"

FAQ

What did Guardant Health (GH) report about Terilyn J. Monroe’s recent stock option exercises?
Terilyn J. Monroe exercised stock options for 46,300 shares of Guardant Health common stock on 2026-08-12, including 32,288 shares at $20.14 and 14,012 shares at $28.61, stemming from 2024 option grants vesting over three years.

How many Guardant Health (GH) shares did Terilyn J. Monroe sell and at what prices?
She sold 46,300 common shares of Guardant Health on 2026-08-12 in multiple open-market or private transactions at weighted average prices ranging from $162.80 to $168.02, across several price brackets detailed in the filing footnotes.

Were Terilyn J. Monroe’s Guardant Health (GH) transactions executed under a Rule 10b5-1 plan?
The filing’s Rule 10b5-1 checkbox is not marked as affirmative, indicating these transactions were not affirmatively reported as conducted under a Rule 10b5-1 trading plan, based on the document-level disclosure provided.

What are the terms of Terilyn J. Monroe’s 2024 Guardant Health (GH) stock option grants?
The February 26, 2024 and November 8, 2024 option awards each vest over three years: 33% of shares vested about one year after grant, and the remaining 67% vest in equal monthly installments over the following two years.

What types of transactions are included in this Guardant Health (GH) Form 4 for Terilyn J. Monroe?
The Form 4 reports two option exercises for 46,300 shares and five separate sale transactions totaling 46,300 common shares, all dated 2026-08-12, with each sale coded as an open-market or private transaction (code S).

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Monroe Terilyn J.
(Last)(First)(Middle)
3100 HANOVER STREET
(Street)
PALO ALTO CALIFORNIA 94304
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Guardant Health, Inc. [ GH ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief People Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/12/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock08/12/2026M32,288A$20.1455,267D
Common Stock08/12/2026M14,012A$28.6169,279D
Common Stock08/12/2026S3,704D$163.4141(1)65,575D
Common Stock08/12/2026S9,934D$164.2712(2)55,641D
Common Stock08/12/2026S19,014D$165.1578(3)36,627D
Common Stock08/12/2026S13,248D$166.1069(4)23,379D
Common Stock08/12/2026S400D$167.9188(5)22,979D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$20.1408/12/2026M32,288 (6)02/26/2034Common Stock32,288$010,916D
Stock Option (Right to Buy)$28.6108/12/2026M14,012 (7)11/08/2034Common Stock14,012$018,615D
Explanation of Responses:
1. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $162.80 to $163.78. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
2. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $163.81 to $164.805. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
3. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $164.825 to $165.82. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
4. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $165.85 to $166.825. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
5. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $167.695 to $168.02. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
6. This represents a stock option award granted on February 26, 2024 that vests over a three-year period. 33% of the shares subject to such award vested on January 2, 2025 and the remaining 67% of the shares vests in equal monthly installments over the remaining two-year period thereafter.
7. This represents a stock option award granted on November 8, 2024 that vests over a three-year period. 33% of the shares subject to such award vested on October 1, 2025 and the remaining 67% of the shares vests in equal monthly installments over the remaining two-year period thereafter.
Remarks:
/s/ John G. Saia, as attorney-in-fact for Terilyn J. Monroe08/13/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR